95
Participants
Start Date
March 27, 2018
Primary Completion Date
April 21, 2021
Study Completion Date
April 21, 2021
FPA150
A monoclonal antibody against B7-H4
Pembrolizumab
An anti-PD1 antibody
National Cancer Center, Gyeonggi-do
Seoul National University Bundang Hospital, Gyeonggi-do
Sarah Cannon Research Institute, Nashville
Karmanos Cancer Institute, Detroit
Orchard Healthcare Research Inc., Skokie
Stephenson Cancer Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio
Utah Cancer Specialists, Salt Lake City
Honor Health, Scottsdale
Cedars-Sinai Medical Center, Los Angeles
UCLA, Los Angeles
Sarcoma Oncology Research Center, Santa Monica
Medical Oncology Associates, PS, Spokane
Yale Cancer Center, New Haven
Severance Hospital, Seoul
ASAN Medical Center, Seoul
Samsung Medical Center, Seoul
Lead Sponsor
Five Prime Therapeutics, Inc.
INDUSTRY